首頁 > 市場調查報告書 > 製藥

開發平台分析

市場調查報告書

商品編碼

1789384

醛固酮合成酶抑制劑市場：按藥物類型、藥物、適應症、開發階段、性別、最終用戶和地區分類

Aldosterone Synthase Inhibitors Market, By Drug Type, By Drug, By Indication, By Stage of Development, By Gender, By End User, By Geography

出版日期: 2025年07月18日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

醛固酮合成酶抑制劑市場規模預計在 2025 年為 2.259 億美元，預計到 2032 年將達到 3.696 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 7.3%。

分析範圍		分析詳細資訊
基準年	2024	市場規模（2025年）	2.259億美元
效能數據	2020-2024	預測期	2025-2032
預測期間的複合年成長率（2025-2032年）	7.30%	預計金額（2032年）	3.696億美元

全球醛固酮合成酶抑制劑市場是一個專業的製藥領域，專注於開發與醛固酮過量生成相關的心血管和腎臟疾病的治療方案。醛固酮合成酶，也稱為CYP11B2，是腎上腺皮質中醛固酮生物合成最後一步的關鍵酶。針對此酵素的抑制劑有望成為治療原發性醛固酮增多症、頑固性高血壓、心臟衰竭和慢性腎臟病等疾病的良藥。這些抑制劑透過選擇性抑制醛固酮生成，同時保留皮質醇合成，與傳統的鹽皮質激素受體拮抗劑相比，其療效更具針對性。

該市場正處於從臨床前研究到臨床試驗的不同發展階段，多家製藥公司已在該治療領域投入大量資金。人們對醛固酮在心血管病理生理學中的作用以及現有治療方案的局限性的認知日益加深，推動著該領域的研究工作。市場成長的關鍵促進因素包括心血管疾病盛行率的上升、對原發性醛固酮增多症認知的不斷加深以及對更有效治療方案的需求。選擇性醛固酮合成酶抑制劑的開發是精準醫療在治療醛固酮相關疾病的重大進展。

市場動態

全球醛固酮合成酶抑制劑市場正經歷顯著成長，這主要歸因於多種因素，其中最主要的是全球心血管疾病盛行率的上升，尤其是難治性高血壓和心臟衰竭。人們越來越認知到，原發性醛固酮增多症是次發性高血壓的更常見病因，其影響著約10-15%的高血壓患者，這導致人們越來越關注醛固酮合成酶抑制劑作為標靶治療介入措施的研究。

此外，現有治療方法的局限性，例如與鹽皮質激素受體拮抗劑相關的副作用，如高血鉀和荷爾蒙分泌受損，為更具選擇性的治療方法創造了機會。然而，市場面臨重大限制，包括新型酵素抑制劑複雜的調控途徑、龐大的研發成本以及需要多年開發才能獲得核准的臨床試驗過程。開發有效靶向醛固酮合成酶同時避免干擾其他類固醇生成酶的選擇性抑制劑所面臨的技術挑戰給製藥公司帶來了額外的障礙。此外，該治療領域的專業性需要廣泛的臨床專業知識和基礎設施，這限制了能夠進行此類開發的公司的數量。

儘管存在這些挑戰，但仍存在大量機遇，如增加對心血管研究的投資、加強製藥公司和機會機構之間的夥伴關係、加深對醛固酮在高血壓以外的各種疾病狀態中的作用的了解，以及可能提高治療效果和患者預後的聯合治療的潛力。

本報告的主要特點

本報告對全球醛固酮合成酶抑制劑市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和複合年成長率。
它還強調了每個領域的潛在商機，並描述了該市場的一系列有吸引力的投資提案。
它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
全球醛固酮合成酶抑制劑市場的主要企業根據以下參數進行分析，例如公司概況、產品系列、主要亮點、財務表現和策略。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、合作夥伴關係、市場擴張和行銷策略做出明智的決策。
「全球醛固酮合成酶抑制劑市場」報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
相關人員可以透過用於分析全球醛固酮合成酶抑制劑市場的各種策略矩陣更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 225.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	7.30%	2032 Value Projection:	USD 369.6 Mn

The global aldosterone synthase inhibitors market represents a specialized pharmaceutical segment focused on developing therapeutic solutions for cardiovascular and renal diseases associated with aldosterone overproduction. Aldosterone synthase, also known as CYP11B2, is a crucial enzyme responsible for the final step in aldosterone biosynthesis within the adrenal cortex. Inhibitors targeting this enzyme offer promising therapeutic potential for treating conditions such as primary aldosteronism, resistant hypertension, heart failure, and chronic kidney disease. These inhibitors work by selectively blocking aldosterone production while preserving cortisol synthesis, providing a more targeted approach compared to traditional mineralocorticoid receptor antagonists.

The market encompasses various developmental stages, from preclinical research to clinical trials, with several pharmaceutical companies investing significantly in this therapeutic area. The growing understanding of aldosterone's role in cardiovascular pathophysiology and the limitations of current treatment options have intensified research efforts in this field. Market growth is primarily driven by increasing prevalence of cardiovascular diseases, rising awareness about primary aldosteronism, and the need for more effective therapeutic alternatives. The development of selective aldosterone synthase inhibitors represents a significant advancement in precision medicine approaches for managing aldosterone-related disorders.

Market Dynamics

The global aldosterone synthase inhibitors market is experiencing significant growth driven by multiple factors, with the primary driver being the increasing prevalence of cardiovascular diseases worldwide, particularly resistant hypertension and heart failure, which affects millions of patients globally and creates substantial demand for innovative therapeutic solutions. The growing recognition of primary aldosteronism as a more common cause of secondary hypertension than previously thought, affecting approximately 10-15% of hypertensive patients, has intensified research focus on aldosterone synthase inhibitors as targeted therapeutic interventions.

Additionally, the limitations of existing treatments, including side effects associated with mineralocorticoid receptor antagonists such as hyperkalemia and hormonal disturbances, create opportunities for more selective therapeutic approaches. However, the market faces significant restraints including complex regulatory pathways for novel enzyme inhibitors, substantial research and development costs, and lengthy clinical trial processes that can extend over several years before market approval. The technical challenges associated with developing selective inhibitors that effectively target aldosterone synthase while avoiding interference with other steroidogenic enzymes present additional hurdles for pharmaceutical companies. Furthermore, the specialized nature of this therapeutic area requires extensive clinical expertise and infrastructure, limiting the number of companies capable of pursuing these developments.

Despite these challenges, opportunities abound in the form of increasing investment in cardiovascular research, growing partnerships between pharmaceutical companies and academic institutions, expanding understanding of aldosterone's role in various disease states beyond hypertension, and the potential for combination therapies that could enhance treatment efficacy and patient outcomes.

Key Features of the Study

This report provides in-depth analysis of the global aldosterone synthase inhibitors market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global aldosterone synthase inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include major pharmaceutical companies, biotechnology firms, and research institutions actively involved in aldosterone synthase inhibitor development.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global aldosterone synthase inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global aldosterone synthase inhibitors market.

Market Segmentation

Drug Type Insights (Revenue, USD Mn, 2020 - 2032)
- Selective Aldosterone Synthase Inhibitors
- Non-Selective CYP11B Inhibitors
Drug Insights (Revenue, USD Mn, 2020 - 2032)
- Osilodrostat
- Lorundrostat
- Baxdrostat
- Vicadrostat
- Dexfadrostat
Indication Insights (Revenue, USD Mn, 2020 - 2032)
- Cushing's Syndrome
- Hypertension
- Primary aldosteronism (Conn's syndrome)
- Heart Failure
- Heart Failure with Reduced Ejection Fraction (HFrEF)
- Heart Failure with Preserved Ejection Fraction (HFpEF)
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Stage of Development Insights (Revenue, USD Mn, 2020 - 2032)
- Preclinical
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Approved or Marketed
Gender Insights (Revenue, USD Mn, 2020 - 2032)
- Male
- Female
End User Insights (Revenue, USD Mn, 2020 - 2032)
- Hospitals
- Cardiology Clinics
- Nephrology Clinics
- Research and Academic Institutes
- Contract Research Organizations (CROs)
Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Mineralys Therapeutics, Inc.
- AstraZeneca
- Boehringer Ingelheim International GmbH
- DAMIAN PHARMA AG
- CORXEL
- JX09
- Recordati Rare Diseases Inc.
- Other Prominent Players

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Aldosterone Synthase Inhibitors Market, By Drug Type
- Global Aldosterone Synthase Inhibitors Market, By Drug
- Global Aldosterone Synthase Inhibitors Market, By Indication
- Global Aldosterone Synthase Inhibitors Market, By Stage of Development
- Global Aldosterone Synthase Inhibitors Market, By Gender
- Global Aldosterone Synthase Inhibitors Market, By End User
- Global Aldosterone Synthase Inhibitors Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends
Pipeline Analysis
Blockade Mapping
Chessboard Mapping
Company Positioning Analysis
Comparative Matrix

4. Global Aldosterone Synthase Inhibitors Market, By Drug Type, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Selective Aldosterone Synthase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Non-Selective CYP11B Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Aldosterone Synthase Inhibitors Market, By Drug, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Osilodrostat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Lorundrostat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Baxdrostat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Vicadrostat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Dexfadrostat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Aldosterone Synthase Inhibitors Market, By Indication, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cushing's Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Primary aldosteronism (Conn's syndrome)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Heart Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  - Heart Failure with Reduced Ejection Fraction (HFrEF)
  - Heart Failure with Preserved Ejection Fraction (HFpEF)
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Aldosterone Synthase Inhibitors Market, By Stage of Development, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Preclinical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Phase I Clinical Trials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Phase II Clinical Trials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Phase III Clinical Trials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Approved or Marketed
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Aldosterone Synthase Inhibitors Market, By Gender, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Aldosterone Synthase Inhibitors Market, By End User, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Cardiology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Nephrology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Aldosterone Synthase Inhibitors Market, By Region, 2020 - 2032, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Drug, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Stage of Development, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2032, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

11. Competitive Landscape

Mineralys Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
DAMIAN PHARMA AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CORXEL
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
JX09
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Recordati Rare Diseases Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Other Prominent Players
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

12. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

13. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

醛固酮合成酶抑制劑市場：按藥物類型、藥物、適應症、開發階段、性別、最終用戶和地區分類

Aldosterone Synthase Inhibitors Market, By Drug Type, By Drug, By Indication, By Stage of Development, By Gender, By End User, By Geography

市場動態

本報告的主要特點

目錄

第1章分析目標與前提條件

第2章市場展望

第3章：市場動態、法規與趨勢分析

4. 全球醛固酮合成酶抑制劑市場按藥物類型分類（以金額為準，2020-2032 年）

5. 全球醛固酮合成酶抑制劑市場按藥物類型分類（以金額為準，2020-2032 年）

6. 全球醛固酮合成酶抑制劑市場依適應症分類（以金額為準，2020-2032）

7. 全球醛固酮合成酶抑制劑市場依發展階段分類（以金額為準，2020-2032 年）

8. 全球醛固酮合成酶抑制劑市場（按性別分類）（以金額為準，2020-2032 年）

9. 全球醛固酮合成酶抑制劑市場（按最終用戶分類）（以金額為準，2020-2032 年）

10. 全球醛固酮合成酶抑制劑市場按地區（以金額為準，2020-2032）

第11章競爭格局

第12章分析師建議

第13章參考文獻與調查方法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Aldosterone Synthase Inhibitors Market, By Drug Type, 2020-2032, (USD Mn)

5. Global Aldosterone Synthase Inhibitors Market, By Drug, 2020-2032, (USD Mn)

6. Global Aldosterone Synthase Inhibitors Market, By Indication, 2020-2032, (USD Mn)

7. Global Aldosterone Synthase Inhibitors Market, By Stage of Development, 2020-2032, (USD Mn)

8. Global Aldosterone Synthase Inhibitors Market, By Gender, 2020-2032, (USD Mn)

9. Global Aldosterone Synthase Inhibitors Market, By End User, 2020-2032, (USD Mn)

10. Global Aldosterone Synthase Inhibitors Market, By Region, 2020 - 2032, Value (USD Mn)

11. Competitive Landscape

12. Analyst Recommendations

13. References and Research Methodology

醛固酮合成酶抑制劑市場：按藥物類型、藥物、適應症、開發階段、性別、最終用戶和地區分類

Aldosterone Synthase Inhibitors Market, By Drug Type, By Drug, By Indication, By Stage of Development, By Gender, By End User, By Geography

市場動態

本報告的主要特點

目錄

第1章 分析目標與前提條件

第2章 市場展望

第3章：市場動態、法規與趨勢分析

4. 全球醛固酮合成酶抑制劑市場按藥物類型分類（以金額為準，2020-2032 年）

5. 全球醛固酮合成酶抑制劑市場按藥物類型分類（以金額為準，2020-2032 年）

6. 全球醛固酮合成酶抑制劑市場依適應症分類（以金額為準，2020-2032）

7. 全球醛固酮合成酶抑制劑市場依發展階段分類（以金額為準，2020-2032 年）

8. 全球醛固酮合成酶抑制劑市場（按性別分類）（以金額為準，2020-2032 年）

9. 全球醛固酮合成酶抑制劑市場（按最終用戶分類）（以金額為準，2020-2032 年）

10. 全球醛固酮合成酶抑制劑市場按地區（以金額為準，2020-2032）

第11章競爭格局

第12章 分析師建議

第13章參考文獻與調查方法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Aldosterone Synthase Inhibitors Market, By Drug Type, 2020-2032, (USD Mn)

5. Global Aldosterone Synthase Inhibitors Market, By Drug, 2020-2032, (USD Mn)

6. Global Aldosterone Synthase Inhibitors Market, By Indication, 2020-2032, (USD Mn)

7. Global Aldosterone Synthase Inhibitors Market, By Stage of Development, 2020-2032, (USD Mn)

8. Global Aldosterone Synthase Inhibitors Market, By Gender, 2020-2032, (USD Mn)

9. Global Aldosterone Synthase Inhibitors Market, By End User, 2020-2032, (USD Mn)

10. Global Aldosterone Synthase Inhibitors Market, By Region, 2020 - 2032, Value (USD Mn)

11. Competitive Landscape

12. Analyst Recommendations

13. References and Research Methodology

第1章分析目標與前提條件

第2章市場展望

第12章分析師建議